- Home
- EQR vs WAT Comparison
EQR vs WAT Comparison
Compare EQR & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- WAT
- Stock Information
- Founded
- EQR 1993
- WAT 1958
- Country
- EQR United States
- WAT United States
- Employees
- EQR N/A
- WAT N/A
- Industry
- EQR Real Estate Investment Trusts
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- EQR Real Estate
- WAT Industrials
- Exchange
- EQR Nasdaq
- WAT Nasdaq
- Market Cap
- EQR 24.7B
- WAT 17.8B
- IPO Year
- EQR 1993
- WAT 1995
- Fundamental
- Price
- EQR $65.29
- WAT $299.57
- Analyst Decision
- EQR Buy
- WAT Hold
- Analyst Count
- EQR 12
- WAT 14
- Target Price
- EQR $76.13
- WAT $374.07
- AVG Volume (30 Days)
- EQR 1.8M
- WAT 582.9K
- Earning Date
- EQR 10-29-2025
- WAT 10-31-2025
- Dividend Yield
- EQR 4.23%
- WAT N/A
- EPS Growth
- EQR 5.58
- WAT 10.77
- EPS
- EQR 2.65
- WAT 11.09
- Revenue
- EQR $3,044,764,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- EQR $4.90
- WAT $7.19
- Revenue Next Year
- EQR $4.00
- WAT $6.40
- P/E Ratio
- EQR $24.69
- WAT $26.89
- Revenue Growth
- EQR 4.40
- WAT 5.89
- 52 Week Low
- EQR $59.41
- WAT $275.05
- 52 Week High
- EQR $78.84
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- EQR 49.11
- WAT 50.63
- Support Level
- EQR $65.56
- WAT $294.96
- Resistance Level
- EQR $67.11
- WAT $303.24
- Average True Range (ATR)
- EQR 1.12
- WAT 8.74
- MACD
- EQR 0.13
- WAT 0.56
- Stochastic Oscillator
- EQR 47.81
- WAT 54.47
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.